- Home
- MDBH vs MRSN Comparison
MDBH vs MRSN Comparison
Compare MDBH & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDBH
- MRSN
- Stock Information
- Founded
- MDBH 1997
- MRSN 2001
- Country
- MDBH United States
- MRSN United States
- Employees
- MDBH N/A
- MRSN N/A
- Industry
- MDBH
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MDBH
- MRSN Health Care
- Exchange
- MDBH Nasdaq
- MRSN Nasdaq
- Market Cap
- MDBH N/A
- MRSN 71.9M
- IPO Year
- MDBH 2023
- MRSN 2017
- Fundamental
- Price
- MDBH $6.16
- MRSN $0.36
- Analyst Decision
- MDBH
- MRSN Buy
- Analyst Count
- MDBH 0
- MRSN 3
- Target Price
- MDBH N/A
- MRSN $4.00
- AVG Volume (30 Days)
- MDBH 2.8K
- MRSN 3.2M
- Earning Date
- MDBH 05-12-2025
- MRSN 03-03-2025
- Dividend Yield
- MDBH N/A
- MRSN N/A
- EPS Growth
- MDBH N/A
- MRSN N/A
- EPS
- MDBH N/A
- MRSN N/A
- Revenue
- MDBH $1,937,885.00
- MRSN $40,497,000.00
- Revenue This Year
- MDBH N/A
- MRSN N/A
- Revenue Next Year
- MDBH N/A
- MRSN $67.68
- P/E Ratio
- MDBH N/A
- MRSN N/A
- Revenue Growth
- MDBH N/A
- MRSN 9.88
- 52 Week Low
- MDBH $5.78
- MRSN $0.37
- 52 Week High
- MDBH $12.00
- MRSN $4.64
- Technical
- Relative Strength Index (RSI)
- MDBH 38.62
- MRSN 32.11
- Support Level
- MDBH $6.33
- MRSN $0.41
- Resistance Level
- MDBH $6.52
- MRSN $0.45
- Average True Range (ATR)
- MDBH 0.10
- MRSN 0.04
- MACD
- MDBH -0.03
- MRSN 0.00
- Stochastic Oscillator
- MDBH 0.00
- MRSN 7.62
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.